Unlocking the future of antibody-drug conjugates

Labcorp bioanalytical services has supported nearly half of the approved antibody - drug conjugates (ADCs) on market today. Access the on-demand session as we discuss LBA and LC-MS insights gleaned from our deep bioanalytical experience with ADCs, bioanalytical opportunities and challenges we have encountered, how innovative strategies can overcome key issues, and a forward-looking perspective on ADC bioanalytical strategies for this rapidly evolving market.

Developments in cardiometabolic care for the primary care physician

The primary care team, including nurse practitioners and physician assistants, is often the first to evaluate and assess chronic conditions and interconnected comorbidities, such as steatotic liver disease, renal disease and Type 2 diabetes (T2D), using diagnostic assays. Use of evidence-based strategies for early detection and effective management of cardiovascular-kidney-metabolic (CKM) conditions is crucial for optimal patient outcomes.

Navigating the nontraditional: A look into fertility challenges and novel referral indications

Hear our subject matter experts share fertility-focused case studies that highlight the challenges and available options for nontraditional families, novel referral indications and how genetic counselors can support patients.

Molecular Tumor Board: 52-year-old male with colon cancer and POLE P286R alteration

Did you know that a subset of patients with microsatellite-stable (MSS) colon cancer have POLE/POLD1 mutations that are associated with high clinical response to immunotherapy?

Join us for this molecular tumor board where we reviewed a case of metastatic MSS-colon cancer with a POLE mutation and high tumor mutational burden, detected on a comprehensive genomic and immune profiling (CGIP) platform. We discuss the incidence and therapeutic significance of POLE/POLD1 proofreading deficiency mutations in patients with colon cancer.

How to interpret unexpected results due to patient metabolism or adulterated urine

How to interpret unexpected negative or positive results

Carrier screening: Providing valuable insights for you and your patients

With early insights and continuing advancements in treatment options, you can help your patients identify the risk of having a child with an inherited genetic disorder. Hear from subject matter experts (including a genetic counselor and a mom of a child with spinal muscular atrophy) about how early carrier screening and genetic counseling can help patients prepare for their reproductive future. 

Solving the puzzle of preeclampsia

Hear from the subject matter experts addressing the prevalence of preeclampsia in the U.S. From early patient education, at-home monitoring and clinical management to digital health intervention and testing for preeclampsia across all pregnancy trimesters—the panelists are shedding light on the work helping to improve pregnancy outcomes and advance health equity.

Overcoming key challenges in global cell and gene therapy trials with Labcorp

Cell and gene therapies (CGT) represent the future of precision medicine, offering the potential to improve patient outcomes across a range of diseases. However, bringing these complex therapies from bench to bedside presents unique challenges at every stage of development. As the CGT landscape continues to evolve rapidly, developers need an experienced partner who can provide integrated solutions to overcome key hurdles at every stage from early research through commercialization. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Franklin, PhD, vice president and enterprise head of CGT at Labcorp, shared how Labcorp’s comprehensive CGT capabilities support all aspects of global CGT development, including preclinical pharmacology, companion diagnostics (CDx) development and validation.

Molecular Tumor Board: 65-year-old male with recurrent hepatocellular carcinoma

In this molecular tumor board, our Medical Affairs Team presents a case of recurrent hepatocellular carcinoma (HCC) with interesting immune phenotypes discovered on a comprehensive genomic and immune profiling test. We reviewed TIGIT as a promising target for cancer immunotherapy and outlined the prognosis and treatment paradigm of HCC along with discussing the different stages and potential barriers of clinical trial enrollment.